Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLX-001 phase 1 PD, safety, tolerability, and PK study in major depressive disorder
NL-OMON59527Phase 1Completed
- Sponsor
- Delix Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of zalsupindole in major depressive disorder (MDD), sponsored by Delix Therapeutics. Primary endpoint: Primary endpoint(s). Started Nov 2024; status: completed.
02
Drugs
zalsupindole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON59527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59527.